Stay updated on MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page.

Latest updates to the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page
- Check7 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.2 instead of v3.7.1. The page continues to show a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check14 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1; the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check34 days agoChange DetectedThe page now displays a 403 Forbidden error in place of the study details, with the addition of standard page chrome such as a 403 header and a Home link in the navigation/footer.SummaryDifference25%

- Check56 days agoChange DetectedThe page now includes additional NIH grant/contract entries for 2019 and 2023, signaling updated funding information for the study; a new Revision tag shows Revision: v3.6.6, replacing the prior v3.6.5.SummaryDifference0.1%

- Check70 days agoChange DetectedPlain Language Summary section removed from the study page, removing a lay-friendly overview of the trial. All other study details remain available on the page.SummaryDifference0.0%

- Check77 days agoChange DetectedThe page revision label updated from v3.6.4 to v3.6.5, indicating a small update to the page without substantive changes to the study information.SummaryDifference0.0%

Stay in the know with updates to MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MK-4830 Monotherapy & Combination With Pembrolizumab Clinical Trial page.